A rare wave of emotion has swept through the global oncology community this year, marked by spontaneous standing ovations at two of the world's most prestigious cancer conferences. In May, during the American Society of Clinical Oncology (ASCO) meeting in Chicago, an entire auditorium rose to applaud results showing a targeted therapy could double survival rates for pancreatic cancer, a tumor historically known for its poor prognosis. This week, the sentiment was repeated in Madrid at the European Society for Medical Oncology (ESMO) congress, where hundreds of oncologists stood to celebrate a trial demonstrating unprecedented survival improvements for the most aggressive form of lung cancer.
Angela Lamarca, coordinator of the Communication Committee for the European congress, noted that while such formal events are typically impartial and contained, the data presented this year was too significant to ignore. "We are seeing an explosion of different drugs," Lamarca explained. "This innovation is not happening only in the most frequent tumors but also in some rarer and more aggressive ones. This is very important and significant." These moments of collective celebration signal a new era where science is finding light in the darkest tumors, offering sustained survival improvements after decades of failed attempts, even if these conditions remain fatal.
The focus in Madrid was on the DeLLphi-305 trial, which presented data on treating small-cell lung cancer (SCLC). The study showed that adding the drug tarlatamab to the immunotherapy durvalumab significantly improved outcomes. Tarlatamab is an antibody that links lymphocytes with malignant cells to destroy them, reinforcing the role of immunotherapy in a disease with few therapeutic alternatives. SCLC is notoriously aggressive, growing so rapidly that 70% of cases are detected at advanced stages, with five-year survival rates not exceeding 5%. However, using the combination of tarlatamab and durvalumab as maintenance therapy after first-line treatment resulted in an estimated overall survival of 79.4% at 12 months, compared to 53.3% for patients receiving only durvalumab.
Stephen Liu, an oncologist at the Georgetown Lombardi Comprehensive Cancer Center, stated in a press release that the observed improvements in survival are of a magnitude never seen before in this type of tumor. Ernest Nadal, scientific director of the Catalan Institute of Oncology and a lung cancer expert present at the conference, described the emotional reaction as a response to a difficult-to-treat disease where this new immunotherapy modality appears to increase the proportion of long-term survivors. "The survival curve doubles: it goes from one year to two," Nadal noted, adding that while the innovation is disruptive, he remains concerned about how long it might take for public systems to finance these treatments.
The enthusiasm in Chicago earlier this year centered on daraxonrasib, a drug targeting the mutated KRAS gene responsible for the aggressive growth of pancreatic and other tumors. The therapy achieved unprecedented success in patients with metastatic disease, extending survival to up to 13 months, double that of conventional chemotherapy. Lamarca, who witnessed the event at the Hospital Universitario Fundación Jiménez Díaz in Madrid, recalled the moment as a paradigm shift. "Seeing those survival curves proves it is a change of paradigm," she said. "As an oncologist, it is a special moment because a light of hope opens up for our patients."
Yannick Buccella, a molecular oncologist, highlighted that daraxonrasib represents a new generation of KRAS inhibitors that are deepening the understanding of tumor biology. He suggested that in the near future, simply stating a patient has pancreatic cancer with a KRAS mutation will be too imprecise; instead, clinicians will need to identify the specific KRAS mutation to predict treatment efficacy. "Precision oncology is becoming more precise," Buccella wrote on X. "Not just one disease or one mutation. Now, a single letter could make the difference."
Despite the excitement, experts maintain caution. Lamarca emphasized that while the survival graphs are clearly superior, these treatments do not cure the tumors; they prolong life. "To someone who is not an oncologist, it might seem like little, but for the patient, living six months longer with better quality of life is a huge change," she stated. These advances buy time for further scientific research, much like immunotherapy did three decades ago.
Recent publications in the New England Journal of Medicine illustrate the potential of this new therapeutic arsenal. Beyond tarlatamab for small-cell lung cancer, studies show that divarasib, a KRAS inhibitor targeting the specific G12C mutation, improves survival before tumor progression in other lung cancer types. Additionally, Antibody-Drug Conjugates (ADCs), which function like a Trojan horse by delivering chemotherapy directly inside malignant cells, have shown promise. When combined with pembrolizumab, one such ADC extended survival before progression to 15 months, compared to just six months with pembrolizumab and chemotherapy alone.
At the ESMO congress, an ADC for advanced endometrial cancer unresponsive to conventional chemo-immunotherapy was also presented. The treatment reduced the risk of disease progression by 41%. Ainhoa Madariaga, an oncologist at Madrid's Hospital 12 de Octubre and a researcher on the study, noted that therapeutic options for this patient population are limited and there is a significant unmet medical need. She affirmed that the results are now robust enough to change clinical practice. Nadal concluded that oncology is witnessing a second wave of innovation similar to the rise of immunotherapy, with a new generation of drugs increasing the rate of long-term survivors.
Sources: El País Ciencia.